NewCardio Awarded Key Patent - Buyout in the works

02.06.2010 14:39
www.finanznachrichten.de/...-congress-on-heart-disease-004.htm

NewCardio Selected to Make Presentations at 15th Annual World Congress on Heart Disease

Presentations Highlight the Company's Advances in Telemedicine

NewCardio, Inc., (OTCBB: NWCI) a cardiac diagnostic technology provider, announced today that two of its most recent medical and technical submissions have been accepted for presentation at the prestigious 15th Annual World Congress on Heart Disease to be held in Vancouver BC on July 24-27, 2010. The Company will present data from both the advanced coronary artery disease (CAD) and atrial fibrillation (AF) clinical studies, with additional information from ongoing CardioBip™ clinical studies. The data supports CardioBip's suitability for long-term monitoring of patients with CAD and AF.

The Company believes that acceptance of these submissions - which present important clinical data supporting the accuracy and effectiveness of its CardioBip product - reflects the growing interest in telemedicine and the recognition of NewCardio's technologies as effective solutions in the field. CardioBip is a unique, hand held device that gives accurate and timely diagnoses of acute cardiac events, and facilitates immediate intervention in life-threatening situations - even when the patient is far removed from a medical care center. Images of the CardioBip are available at www.newcardio.com/products-cardio-bip.php.

Branislav Vajdic, Ph.D., NewCardio's CEO, commented, "Our acceptance to the 15th Annual World Congress on Heart Disease reflects the remarkable and ongoing success of our academic medical collaborators, and our technical and scientific teams. We believe that they will provide strong technical and clinical evidence supporting the potential of CardioBip as a key telemedicine solution for monitoring patients with very serious and unfortunately common cardiac diseases. CardioBip, without any leads and wires, is patient tolerable and provides reconstructed full 12-lead ECG data. Many cardiac patients would benefit from this improved diagnostic tool and its better long-term monitoring options."

The Congress will provide the opportunity for a comprehensive overview of the latest research developments in cardiovascular medicine, primarily in the areas of molecular biology, coronary artery disease, heart failure, cardiac arrhythmias and cardiac surgery.

... (weiter siehe LINK!)

29.07.2010 18:16
www.finanznachrichten.de/...trategic-relationships-and-008.htm

NewCardio Announces New $1.5 Million Line of Credit with Existing Shareholders / Strengthens Company's Position for Strategic Relationships and Facilitates Ongoing Commercialization of QTinno

SANTA CLARA, Calif., July 29 /PRNewswire-FirstCall/ -- NewCardio, Inc., (BULLETIN BOARD: NWCI) a cardiac diagnostic technology provider, today announced that it has entered into a new line of credit with three of its existing shareholders, one of which is represented on the Board of Directors, to strengthen its financial position. This will allow the company further time to fully commercialize its lead solution, QTinno(TM).

In conjunction with signing this credit line, the company withdrew the S-1 registration statement, previously filed with the Securities and Exchange Commission (SEC) as it does not currently intend to pursue the public offering. Management believes that the company has sufficient operating capital to sustain its operations and fund its business plan at this time.

The credit facility is part of a series of steps designed to improve the company's ability to identify and attract potential strategic relationships and/or investors, which is intended to enable the company to maximize the value to be derived through continued development of its 3D platform technology.

...(weiter siehe LINK)